Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryCommunity-Care Elevidys Coverage Prior Auth | Open…
    Ask Trek AI about this page
    CurrentCommunity-CarePolicy N/A

    Delandistrogene moxeparvovec (Elevidys) — Coverage Criteria for Duchenne muscular dystrophy

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This medical benefit medication utilization policy defines coverage criteria, quantity limits, and authorization period for delandistrogene moxeparvovec (Elevidys) for members with Duchenne muscular dystrophy (DMD). It applies to providers seeking prior authorization for this therapy.

    Policy Summary
    PayerCommunity-Care
    PolicyDelandistrogene moxeparvovec (Elevidys) — Coverage Criteria for Duchenne muscular dystrophy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewSep 1, 2024
    Next Review DateSep 1, 2024
    Key ActionSubmit prior authorization demonstrating all coverage criteria are met, including genetic test results and anti-AAVrh74 titer <1:400.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥4minimum patient age for therapy
    1 kitquantity limit per lifetime
    1 moauthorization period if approved

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    <1:400required antibody titer threshold
    J1413HCPCS code

    Coverage Criteria for delandistrogene moxeparvovec (Elevidys)

    Initial Therapy

    Covered when ALL of the following are met for initial approval:

    Approval note: All criteria must be met for approval

    Coverage is not allowed for patients whose DMD gene mutation is a deletion involving exon 8 and/or exon 9. Genetic testing documentation must confirm the specific DMD mutation and demonstrate that the mutation is not a deletion in exon 8 and/or exon 9 to meet eligibility for delandistrogene moxeparvovec (Elevidys).

    Treatment with delandistrogene moxeparvovec (Elevidys) is not indicated when the coverage criteria are not met. Common reasons for denial include: anti-AAVrh74 total binding antibody titers ≥ 1:400, patient age < 4 years, documented non-ambulatory status or requirement for an assistive device, prior treatment with delandistrogene moxeparvovec, or failure to discontinue or plan to continue exon-skipping therapies prior to gene therapy.

    Coding and Laboratory Thresholds

    Applicable HCPCS CodesHCPCSCovered
    J1413Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose
    inv-05: Anti-AAVrh74 total binding antibody titer
    Required titer cutoffAnti-AAVrh74 total binding antibody <1:400
    Measurement typeTotal binding antibody titer (serologic)
    Interpretation for eligibilityResults must show titer less than 1:400 (not elevated) to meet coverage criteria

    Provider Actions, Documentation, and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required before Elevidys (delandistrogene moxeparvovec) will be covered. Submit clinical documentation demonstrating the member meets all coverage criteria (diagnosis, genetic testing, antibody titers, age, ambulatory status, prior treatment history, and specialist involvement) as part of the authorization request.

    • Submit genetic testing confirming a DMD gene mutation and that the mutation is not a deletion in exon 8 and/or exon 9.
    • Provide anti-AAVrh74 total binding antibody titer results showing <1:400.
    • Document patient age (must be ≥ 4 years) and that treatment is prescribed by, or in consultation with, a neurologist.
    • Include confirmation (medical records or chart notes) that the member is ambulatory without an assistive device.
    • Document that the member has not previously received delandistrogene moxeparvovec.
    • List any current exon-skipping therapies and confirm planned discontinuation prior to Elevidys administration.

    Definitions and Key Clinical Terms

    inv-11: Ambulatory
    DefinitionAmbulatory = patient is able to walk without needing an assistive device (e.g., without side-by-side assist, cane, walker, wheelchair).
    How to confirmConfirmation via medical records or chart notes documenting the patient ambulates without assistive devices is required.
    Relevance to coverageAmbulatory status is required for initial approval of delandistrogene moxeparvovec (Elevidys).
    inv-12: Anti-AAVrh74 total binding antibody
    What it isSerologic measurement of anti-AAVrh74 total binding antibody titer.
    Eligibility cutoffMust be less than 1:400 (total binding antibody <1:400).
    Policy implication

    Background

    Duchenne muscular dystrophy (DMD) is a genetic neuromuscular disorder caused by mutations in the DMD gene. Delandistrogene moxeparvovec (Elevidys) is a single-dose gene therapy intended for eligible ambulatory patients with DMD who meet specific genetic and immunologic criteria, including a DMD mutation that is not a deletion in exon 8 and/or exon 9 and an anti-AAVrh74 total binding antibody titer < 1:400. Additional requirements for treatment include age ≥ 4 years, prescription by or consultation with a neurologist, no prior exposure to delandistrogene moxeparvovec, and discontinuation of exon-skipping therapies before treatment.

    Policy Summary
    PayerCommunity-Care
    PolicyDelandistrogene moxeparvovec (Elevidys) — Coverage Criteria for Duchenne muscular dystrophy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewSep 1, 2024
    Next Review DateSep 1, 2024
    Key ActionSubmit prior authorization demonstrating all coverage criteria are met, including genetic test results and anti-AAVrh74 titer <1:400.
    SourceLink
    On This Page
    Coverage Criteria for delandistrogene moxeparvovec (Elevidys)Coding and Laboratory ThresholdsProvider Actions, Documentation, and AuthorizationDefinitions and Key Clinical TermsBackground
    Denial Risk

    Triggers for Denial

    Requests will be denied when required coverage criteria or documentation are missing, or when specific exclusion conditions apply.

    • Missing or incomplete prior authorization request or lacking required documentation (genetic testing, antibody titer, neurologist involvement, ambulatory confirmation, prior treatment history).
    • Anti-AAVrh74 total binding antibody titer ≥ 1:400.
    • Patient younger than 4 years of age at time of request.
    • Genetic testing shows a deletion in exon 8 and/or exon 9 of the DMD gene.
    • Member has previously been treated with delandistrogene moxeparvovec.
    • Exon-skipping therapies are not discontinued prior to planned Elevidys treatment or are planned to be re-initiated after Elevidys.
    Elevated titers (≥1:400) render treatment not indicated per policy criteria.